Viking Therapeutics Inc (VKTX) short interest is $237 million; 26.13 million shares shorted; 43.69% short interest % of float; 2.15% stock borrow fee.
VKTX shares shorted increased by 1.7 million shares this week, +7.16%, even as its stock price rose by +14%.
VKTXâ€™s stock price spike is partially due to Gilead Scienceâ€™s (GILD) Phase 3 liver treatment trial failed, making Vikingâ€™s fatty liver Phase 2 trial an attractive binary bet (as can be seen by the increased call option volume in the stock.)
Shorts have come into the name on the heels of a week that was up 14% which makes up most of this yearâ€™s +19% move and are looking for the stock to take a breather and give back some of its recent gains.
We are seeing continued short selling this morning as short sellers continue to build their positions. If long buyers run out of steam, we should see continued short side activity and pressure and a sharp spike down in VTXâ€™s stock price.
Want deeper insight into the above analysis?
Contact:Â [email protected]
Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Managing Director Predictive Analytics, S3 Partners, LLC
For more information on S3â€™s reporting, data and analytics solutions, email us at [email protected]. Start your free trial of the BLACK App â€“ the only source of real-time short interest on the Bloomberg Terminal or Thomson Reuters Eikon.
For short side data and access to our research reports go to https://shortsight.com/